Ocugen, Inc. (OCGN) gained in the pre-market after announcing the fourth quarter and fiscal 2021 results. OCGN values at $3.17 gained more than 3.92% compared
Ocugen, Inc. (OCGN) is a late-stage biotherapeutics company engaged in the discovery, development, and commercialization of gene therapies to treat blindness-related diseases. The company is
Ocugen, Inc. (OCGN) is a leading innovative clinical-stage biopharmaceutical company. It is primarily focused on the discovery, development, and commercialization of treatments for multiple retinal
Ocugen Inc. (OCGN) stock gained a further 16.03% in the after-hours at $6.08 on December 17. The stock seems to continue gaining on its Covid-19
The shares of Ocugen Inc. (OCGN) are up 3.58% to $6.67 in early trading this morning. The Ocugen stock was down by -4.17% to $6.44
Ocugen Inc. (OCGN) shares gained 13.85% in after-hours on Friday, July 2, 2021, and closed at $8.30 per share. Earlier in the morning session on
Shares of Ocugen, Inc. (OCGN) stock were down in the per market trading session today after recording the gain of 6.69% with an $11.96 per
In the premarket trading session, Ocugen Inc. (OCGN) stock soared by 20.56% to trade at $11.61at the time of writing. OCGN closed Friday’s session at
Ocugen (OCGN) stock is a relatively new biotechnology company specializing in diverse and lucrative fields such as gene therapy and Covid 19 vaccines. In February,
Ocugen, Inc. (OCGN) was up another 60% in aftermarket trading on Friday after the company announced it had signed definitive agreements for the sale of
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.